{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,30]],"date-time":"2025-12-30T04:02:36Z","timestamp":1767067356014,"version":"3.48.0"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,22]],"date-time":"2025-11-22T00:00:00Z","timestamp":1763769600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,12,30]],"date-time":"2025-12-30T00:00:00Z","timestamp":1767052800000},"content-version":"vor","delay-in-days":38,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Relapse is a major cause of treatment failure in high-risk acute myeloid leukemia (AML) after hematopoietic stem cell transplantation (HSCT). Natural killer (NK) cell immunotherapy may enhance graft-versus-leukemia (GvL) effects without increasing graft-versus-host disease (GvHD). This study assessed the safety and feasibility of early post-HSCT prophylactic infusions of third-party NK cells in high-risk AML.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>In a single-arm, non-randomized trial, 11 high-risk AML patients received two doses of ex vivo expanded third-party NK cells (5\u2009\u00d7\u200910\u2076 cells\/kg) on days 6 and 12 post-HSCT. Endpoints included safety (CTCAE v5.0), relapse incidence, overall survival (OS), and disease-free survival (DFS). NK cell products were assessed for purity (\u2265\u200980% CD56\u207aCD3\u207b), cytotoxicity (K562 assay), and expansion.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      NK cell infusion was well tolerated, with no grade 3 or higher infusion-related toxicities. Acute GvHD (Grade 1\u20132) occurred in 36.4% (4\/11); chronic GvHD in 27.3% (3\/11). CMV reactivation occurred in 45.5% (5\/11) and was managed preemptively. At a median 256-day follow-up (54\u2013514), Relapse occurred in 27.3% (3\/11; median: 111 days). Survival was significantly better in patients in CR1\/CR2 at HSCT (83.3%) compared to those not in remission (20%;\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.02).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Early prophylactic NK cell infusions post-HSCT are safe and feasible. Although relapse incidence remains substantial, outcomes appear improved versus historical data. Future randomized trials must confirm clinical benefits and refine timing\/dosing strategies.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12885-025-15362-8","type":"journal-article","created":{"date-parts":[[2025,11,22]],"date-time":"2025-11-22T06:32:54Z","timestamp":1763793174000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Evaluating the safety and feasibility of prophylactic third-party NK cell administration in high-risk AML patients post-HSCT"],"prefix":"10.1186","volume":"25","author":[{"given":"Maryam","family":"Barkhordar","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shima","family":"Tavoosi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shirin","family":"Tavakoli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maryam Samareh","family":"Salavatipour","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tanaz","family":"Bahri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bahram","family":"Chahardouli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amir Hossein","family":"Baghsheikhi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohammad","family":"Vaezi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Davoud","family":"Babakhani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Soroush","family":"Rad","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Seied Asadollah","family":"Mousavi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ghasem","family":"Janbabai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hossein","family":"Salehi-Shadkami","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohammad","family":"Ahmadvand","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,11,22]]},"reference":[{"issue":"12","key":"15362_CR1","doi-asserted-by":"publisher","first-page":"1136","DOI":"10.1056\/NEJMra1406184","volume":"373","author":"H D\u00f6hner","year":"2015","unstructured":"D\u00f6hner H, Weisdorf DJ, Bloomfield CD. Acute myeloid leukemia. N Engl J Med. 2015;373(12):1136\u201352.","journal-title":"N Engl J Med"},{"issue":"2","key":"15362_CR2","doi-asserted-by":"publisher","first-page":"159","DOI":"10.2217\/fon-2022-0565","volume":"19","author":"C Dharmani","year":"2023","unstructured":"Dharmani C, Wang E, Tu N, Salas M, Kamel YM. Characteristics and outcomes of elderly patients with acute myeloid leukemia who receive no treatment in the Surveillance, epidemiologyand end Results-Medicare database. Future Oncol. 2023;19(2):159\u201371.","journal-title":"Future Oncol"},{"issue":"4","key":"15362_CR3","first-page":"424","volume":"129","author":"H D\u00f6hner","year":"2017","unstructured":"D\u00f6hner H, Estey E, Grimwade D, Amadori S, Appelbaum FR, B\u00fcchner T, et al. Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood J Am Soc Hematol. 2017;129(4):424\u201347.","journal-title":"Blood J Am Soc Hematol"},{"issue":"7","key":"15362_CR4","doi-asserted-by":"publisher","first-page":"1907","DOI":"10.1007\/s00277-023-05226-1","volume":"102","author":"K Duda","year":"2023","unstructured":"Duda K, Wieczorkiewicz-Kabut A, Kocl\u0119ga A, Zieli\u0144ska P, Wo\u017aniczka K, Krzemie\u0144 H, et al. Allogeneic hematopoietic stem cell transplantation remains a feasible approach for elderly with acute myeloid leukemia: a 10-year experience. Ann Hematol. 2023;102(7):1907\u201314.","journal-title":"Ann Hematol"},{"key":"15362_CR5","doi-asserted-by":"crossref","unstructured":"Kommuru S, Sagireddy S, Patel AM, Thoutam HR, Yasmeen S, Jarrad AA, et al. Utilization of hematopoietic stem cell transplantation for acute myeloid leukemia and related hospital outcomes: A Cross-Sectional study of US hospitals. Cureus. 2022;14(12):e32821.","DOI":"10.7759\/cureus.32821"},{"issue":"7","key":"15362_CR6","doi-asserted-by":"publisher","first-page":"1419","DOI":"10.3390\/cancers16071419","volume":"16","author":"C Antier","year":"2024","unstructured":"Antier C, Jullien M, Tessoulin B, Loirat M, Peterlin P, Garnier A, et al. Late relapse after allogeneic stem cell transplantation in patients treated for acute myeloid leukemia: relapse Incidence, Characteristics, role of conditioning Regimen, and outcome. Cancers. 2024;16(7):1419.","journal-title":"Cancers"},{"issue":"10","key":"15362_CR7","first-page":"1053","volume":"131","author":"S Cooley","year":"2018","unstructured":"Cooley S, Parham P, Miller JS. Strategies to activate NK cells to prevent relapse and induce remission following hematopoietic stem cell transplantation. Blood J Am Soc Hematol. 2018;131(10):1053\u201362.","journal-title":"Blood J Am Soc Hematol"},{"key":"15362_CR8","doi-asserted-by":"publisher","first-page":"1869","DOI":"10.3389\/fimmu.2018.01869","volume":"9","author":"AM Abel","year":"2018","unstructured":"Abel AM, Yang C, Thakar MS, Malarkannan S. Natural killer cells: development, maturation, and clinical utilization. Front Immunol. 2018;9:1869.","journal-title":"Front Immunol"},{"key":"15362_CR9","doi-asserted-by":"crossref","unstructured":"Xu Y, Wang L, Li W, Chen B, Liu Y, Wang H, et al. Killer immunoglobulin-like receptors\/human leukocyte antigen class-I, a crucial immune pathway in cancer. Annals Translational Med. 2020;8(5):244.","DOI":"10.21037\/atm.2020.01.84"},{"issue":"1","key":"15362_CR10","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1186\/s40814-023-01355-6","volume":"9","author":"M Ahmadvand","year":"2023","unstructured":"Ahmadvand M, Barough MS, Hashemi ZS, Sanati H, Abbasvandi F, Yunesian M, et al. Safety and feasibility study of ex vivo expanded allogeneic-NK cells infusion in patients with acute pneumonia caused by COVID-19. Pilot Feasibility Stud. 2023;9(1):137.","journal-title":"Pilot Feasibility Stud"},{"issue":"10","key":"15362_CR11","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1016\/j.humimm.2022.07.006","volume":"83","author":"QJ Zhang","year":"2022","unstructured":"Zhang QJ. Donor selection based on NK alloreactivity for patients with hematological malignancies. Hum Immunol. 2022;83(10):695\u2013703.","journal-title":"Hum Immunol"},{"key":"15362_CR12","doi-asserted-by":"publisher","first-page":"1207276","DOI":"10.3389\/fimmu.2023.1207276","volume":"14","author":"M Zhang","year":"2023","unstructured":"Zhang M, Lam K-P, Xu S. Natural killer cell engagers (NKCEs): a new frontier in cancer immunotherapy. Front Immunol. 2023;14:1207276.","journal-title":"Front Immunol"},{"issue":"1","key":"15362_CR13","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1038\/s41375-021-01349-4","volume":"36","author":"SO Ciurea","year":"2022","unstructured":"Ciurea SO, Kongtim P, Soebbing D, Trikha P, Behbehani G, Rondon G, et al. Decrease post-transplant relapse using donor-derived expanded NK-cells. Leukemia. 2022;36(1):155\u201364.","journal-title":"Leukemia"},{"issue":"12","key":"15362_CR14","first-page":"3273","volume":"118","author":"A Curti","year":"2011","unstructured":"Curti A, Ruggeri L, D\u2019Addio A, Bontadini A, Dan E, Motta MR, et al. Successful transfer of alloreactive haploidentical KIR ligand-mismatched natural killer cells after infusion in elderly high risk acute myeloid leukemia patients. Blood J Am Soc Hematol. 2011;118(12):3273\u20139.","journal-title":"Blood J Am Soc Hematol"},{"issue":"12","key":"15362_CR15","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1182\/blood.2022016867","volume":"140","author":"H D\u00f6hner","year":"2022","unstructured":"D\u00f6hner H, Wei AH, Appelbaum FR, Craddock C, DiNardo CD, Dombret H,\u00a0et al. Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN. Blood. 2022;140(12):1345\u201377.","journal-title":"Blood"},{"issue":"1","key":"15362_CR16","first-page":"51","volume":"15","author":"M Barkhordar","year":"2021","unstructured":"Barkhordar M, Kasaeian A, Tavakoli S, Vaezi M, Foumani HK, Bahri T, et al. Selection of suitable alternative donor in the absence of matched sibling donor: A retrospective single-center study to compare between haploidentical, 10\/10 and 9\/10 unrelated donor transplantation. Int J Hematology-Oncology Stem Cell Res. 2021;15(1):51.","journal-title":"Int J Hematology-Oncology Stem Cell Res"},{"key":"15362_CR17","doi-asserted-by":"crossref","unstructured":"Barkhordar M, Kasaeian A, Janbabai G, Kamranzadeh Fumani H, Tavakoli S, Rashidi AA, et al. Modified combination of anti-thymocyte globulin (ATG) and post-transplant cyclophosphamide (PTCy) as compared with standard ATG protocol in haploidentical peripheral blood stem cell transplantation for acute leukemia. Front Immunol. 2022;13:921293.","DOI":"10.3389\/fimmu.2022.921293"},{"issue":"3","key":"15362_CR18","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1038\/nri1570","volume":"5","author":"P Parham","year":"2005","unstructured":"Parham P. MHC class I molecules and KIRs in human history, health and survival. Nat Rev Immunol. 2005;5(3):201\u201314.","journal-title":"Nat Rev Immunol"},{"key":"15362_CR19","doi-asserted-by":"publisher","first-page":"232470962513800","DOI":"10.1177\/23247096251380031","volume":"13","author":"M Azari","year":"2025","unstructured":"Azari M, Azari M, Alijani N, Shafaroudi P, Sefidbakht S, Barkhordar M, et al. Diagnostic challenges in Post-Transplant extranodal NK\/T-Cell lymphoma following haploidentical hematopoietic stem cell transplantation for acute myeloid leukemia: A case report. J Investig Med High Impact Case Rep. 2025;13:23247096251380031.","journal-title":"J Investig Med High Impact Case Rep"},{"key":"15362_CR20","doi-asserted-by":"publisher","first-page":"1066285","DOI":"10.3389\/fonc.2022.1066285","volume":"12","author":"E Maffini","year":"2022","unstructured":"Maffini E, Ursi M, Barbato F, Dicataldo M, Roberto M, Campanini E, et al. The prevention of disease relapse after allogeneic hematopoietic cell transplantation in acute myeloid leukemia. Front Oncol. 2022;12:1066285.","journal-title":"Front Oncol"},{"issue":"8","key":"15362_CR21","doi-asserted-by":"publisher","first-page":"1834","DOI":"10.1158\/1078-0432.CCR-17-3196","volume":"24","author":"AT Bj\u00f6rklund","year":"2018","unstructured":"Bj\u00f6rklund AT, Carlsten M, Sohlberg E, Liu LL, Clancy T, Karimi M, et al. Complete remission with reduction of High-Risk clones following haploidentical NK-Cell therapy against MDS and AML. Clin Cancer Res. 2018;24(8):1834\u201344.","journal-title":"Clin Cancer Res"},{"issue":"5562","key":"15362_CR22","doi-asserted-by":"publisher","first-page":"2097","DOI":"10.1126\/science.1068440","volume":"295","author":"L Ruggeri","year":"2002","unstructured":"Ruggeri L, Capanni M, Urbani E, Perruccio K, Shlomchik WD, Tosti A, et al. Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants. Science. 2002;295(5562):2097\u2013100.","journal-title":"Science"},{"issue":"1","key":"15362_CR23","doi-asserted-by":"publisher","first-page":"1090","DOI":"10.1186\/s12885-023-11610-x","volume":"23","author":"M Ahmadvand","year":"2023","unstructured":"Ahmadvand M, Barough MS, Barkhordar M, Faridfar A, Ghaderi A, Jalaeikhoo H, et al. Phase I non-randomized clinical trial of allogeneic natural killer cells infusion in acute myeloid leukemia patients. BMC Cancer. 2023;23(1):1090.","journal-title":"BMC Cancer"},{"issue":"1","key":"15362_CR24","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s12672-024-01698-3","volume":"16","author":"S Tavakoli","year":"2025","unstructured":"Tavakoli S, Samareh-Salavatipour M, Mardi A, Salehi-Shadkami H, Vaezi M, Barkhordar M, et al. Evaluating the safety and feasibility of allogeneic NK cell infusion in high-risk lymphoma patients post-autologous stem cell transplantation. Discover Oncol. 2025;16(1):1\u201311.","journal-title":"Discover Oncol"},{"issue":"7","key":"15362_CR25","doi-asserted-by":"publisher","first-page":"1290","DOI":"10.1016\/j.bbmt.2016.04.009","volume":"22","author":"DA Lee","year":"2016","unstructured":"Lee DA, Denman CJ, Rondon G, Woodworth G, Chen J, Fisher T, et al. Haploidentical natural killer cells infused before allogeneic stem cell transplantation for myeloid malignancies: a phase I trial. Biol Blood Marrow Transplant. 2016;22(7):1290\u20138.","journal-title":"Biol Blood Marrow Transplant"},{"key":"15362_CR26","doi-asserted-by":"publisher","first-page":"096368972311981","DOI":"10.1177\/09636897231198178","volume":"32","author":"U Kulkarni","year":"2023","unstructured":"Kulkarni U, Arunachalam AK, Palani HK, Nair RR, Balasundaram N, Venkatraman A, et al. Haploidentical natural killer cell therapy as an adjunct to stem cell transplantation for treatment of refractory acute myeloid leukemia. Cell Transplant. 2023;32:09636897231198178.","journal-title":"Cell Transplant"},{"key":"15362_CR27","doi-asserted-by":"crossref","unstructured":"Shapiro RM, Birch GC, Hu G, Cadavid JV, Nikiforow S, Baginska J, et al. Expansion, persistence, and efficacy of donor memory-like NK cells infused for posttransplant relapse. J Clin Investig. 2022;132(11):e154334.","DOI":"10.1172\/JCI154334"},{"issue":"8","key":"15362_CR28","doi-asserted-by":"publisher","first-page":"1581","DOI":"10.1016\/j.bbmt.2018.03.019","volume":"24","author":"TA Fehniger","year":"2018","unstructured":"Fehniger TA, Miller JS, Stuart RK, Cooley S, Salhotra A, Curtsinger J, et al. A phase 1 trial of CNDO-109-Activated natural killer cells in patients with High-Risk acute myeloid leukemia. Biol Blood Marrow Transpl. 2018;24(8):1581\u20139.","journal-title":"Biol Blood Marrow Transpl"},{"issue":"1","key":"15362_CR29","first-page":"42","volume":"52","author":"F Gierschek","year":"2024","unstructured":"Gierschek F, Schlueter J, K\u00fchnel I, Feigl FF, Schmiedel D, Pr\u00fcfer M, et al. Empowering natural killer cells to combat acute myeloid leukemia: perspective on CAR-NK cell therapy. Transfus Med Hemotherapy. 2024;52(1):42\u201360.","journal-title":"Transfusion Medicine and Hemotherapy"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-025-15362-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12885-025-15362-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-025-15362-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,30]],"date-time":"2025-12-30T03:36:03Z","timestamp":1767065763000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12885-025-15362-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,22]]},"references-count":29,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["15362"],"URL":"https:\/\/doi.org\/10.1186\/s12885-025-15362-8","relation":{},"ISSN":["1471-2407"],"issn-type":[{"type":"electronic","value":"1471-2407"}],"subject":[],"published":{"date-parts":[[2025,11,22]]},"assertion":[{"value":"21 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 November 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study will be conducted by the principles of the Declaration of Helsinki and Good Clinical Practice guidelines. Ethical approval will be obtained from the Institutional Review Board of Tehran University. Informed consent will be obtained from all participants before enrollment, and their privacy and confidentiality will be maintained throughout the study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not Applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"1931"}}